EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
https://doi.org/10.14412/1995-4484-2014-99-101
Abstract
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with chronic tophacaceous gout resistant to therapy with nonsteroidal anti-inflammatory drugs, glucocorticoids, and
colchicine. The results show a good and long-term clinical effect of the drug, which includes reduction of the number of painful and swollen joints and the absence of exacerbations during trial of the therapy of hyperuricemia.
About the Authors
Maksim Sergeyevna EliseevRussian Federation
O V Zhelyabin
Russian Federation
V G Barskova
Russian Federation
E L Nasonov
Russian Federation
References
1. <div><p>Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Reumatol Port. 2010;35(5):466–74.</p><p>Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907–12. DOI: 10.1136/ard.2010.128454.</p><p>Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011;12:103. DOI: 10.1186/1471-2474-12-103.</p><p>Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология. 2012;50(6):15–8. [Barskova VG, Eliseyev MS, Denisov IS. Yhe rate of metabolic syndrome and comorbidities in patients with gout: data of a multicenter trial. Rheumatology Science and Practice. 2012;50(6):15–8.]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1287.</p><p>Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Med. 2010;26(12):2813–21. DOI: 10.1185/03007995.2010.533647.</p><p>Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31(12):2429–32.</p><p>Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22(5):908–14.</p><p>So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum. 2010;62(10):3064–76. DOI: 10.1002/art.27600.</p><p>Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48. DOI: 10.1136/annrheumdis-2011-200908.</p><p>Sunkureddi P, Bardin T, Alten R, et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3. Ann Rheum Dis. 2012;71(Suppl 3):447. DOI: 10.1136/annrheumdis-2011-200908.</p></div><br />
Review
For citations:
Eliseev M.S., Zhelyabin O.V., Barskova V.G., Nasonov E.L. EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT. Rheumatology Science and Practice. 2014;52(1):99-101. (In Russ.) https://doi.org/10.14412/1995-4484-2014-99-101